Form 4: Serina Therapeutics CSO Exercises Options, Sells Shares in Pre-Planned Transaction

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold the acquired common stock in a pre-planned transaction.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc. (SER), engaged in a transaction on July 28, 2025.
• Exercised 6,500 stock options at an exercise price of $0.06 per share; these options were fully vested.
• Immediately sold the 6,500 shares of common stock acquired from the option exercise.
• The shares were sold at a weighted average price of $5.89 per share, with individual sales ranging from $5.60 to $6.02.
• Following these transactions, Randall Moreadith's direct beneficial ownership of common stock is 0 shares, while beneficial ownership of stock options is 488,686.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (exercise and sell) which is common for executives. While insider selling can sometimes be viewed negatively, this appears to be a pre-planned transaction for liquidity/diversification rather than a signal of negative company performance. The executive still holds a significant number of options.

Positives

• The significant difference between the option exercise price ($0.06) and the sale price ($5.89) indicates a substantial gain for the reporting person on this specific transaction.

Negatives

• The Chief Scientific Officer sold all shares acquired from the option exercise, resulting in zero direct beneficial ownership of common stock after the transaction.
• Insider selling, even if pre-planned, can sometimes be perceived negatively by investors as it might suggest a lack of confidence, though in this case, it appears to be a common practice for liquidity and diversification.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general implications of insider transactions.

Future Outlook

Not applicable; this filing reports past insider transactions and does not provide forward-looking statements or guidance.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

This Form 4 filing details a routine insider transaction where an executive exercises vested stock options and sells the acquired shares, often for personal financial planning, diversification, or liquidity. Such transactions are common across all industries for executives with equity compensation.

Comparison to Industry Standards

• This is a standard insider transaction (exercise and sell) often executed under a Rule 10b5-1 plan, which is a common practice for corporate insiders to manage their equity holdings and avoid accusations of trading on material non-public information. There are no specific comparable companies or projects mentioned in this filing to assess against industry standards.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a negative signal, though it's a common practice for executives to monetize vested options. The transaction was pre-planned under a Rule 10b5-1 plan, which mitigates concerns about trading on inside information.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing.

Key Dates

Keywords

Serina Therapeutics, SER, Randall Moreadith, Chief Scientific Officer, CSO, insider trading, Form 4, stock option exercise, share sale, beneficial ownership